TNGX - Company ID 0001819133
The table below shows Tango Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $62.38M | $42.07M | $36.53M | $24.86M | $37.04M | $7.66M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $132.16M | $143.92M | $115.20M | $105.91M | $77.64M | $49.99M |
| SG&A |
Tango Therapeutics, Inc. reported annual revenue of $62.38M for fiscal year 2025. That is up 48.3% from $42.07M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $7.66M (FY 2020) to $62.38M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $41.51M |
| $43.75M |
| $35.50M |
| $30.02M |
| $17.60M |
| $9.87M |
| Operating income | -$111.29M | -$145.59M | -$114.17M | -$111.07M | -$58.19M | -$52.20M |
| Income tax | $4.00K | $208.00K | $134.00K | $54.00K | $292.00K | $0.00 |
| Net income | -$101.60M | -$130.30M | -$101.70M | -$108.18M | -$58.23M | -$51.97M |
| EPS (diluted) | -$0.87 | -$1.19 | -$1.08 | -$1.23 | -$0.94 | - |